anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
ACZONE™ (dapsone) Gel, 5% will be applied to one elbow or knee, randomized at time of enrollment. Application will be topical to the same location twice daily (morning and evening) for six weeks.
Part 2: Participants receive multiple SC doses of efinopegdutide titrated from Dosage 1, Dosage 2, Dosage 3, Dosage 4, Dosage 5, or Dosage 6. Participants receive a SC dose of efinopegdutide, Dosage 1 on Days 1 and 8; Dosage 2 on Days 15 and 22; Dosage 3 on Days 29, 36, 43 and 50; Dosage 4 on Days 57, 64, 71 and 78; Dosage 5 on Days 85, 92, 99, 106; and Dosage 6 on Days 113, 120, 127, and 134. Participants also receive oral acetaminophen on Day -2, Day 6, 62, and 83.
FIELD: biotechnology, medicine, gynecology. SUBSTANCE: from the strain of Lactobacillus fermentum 90-Ts-4 that is a producer of an eubiotic preparation lactobacterin a variant is selected. This variant is agglutinated in the presence of concanavaline-A and shows high adhesive property with respect to vaginal epithelium. Characteristics are stable. The strain shows the more rate growth as compared with that of the parent one that is a positive property for production of the preparation. Invention can be used in medicine, gynecological practice for treatment of patients with disbacteriosis. EFFECT: high adhesive property. 2 tbl, 2 ex
PURPOSE: Childhood spoken language interventions and augmentative and alternative communication (AAC) interventions share a common purpose: maximizing communication and language outcomes. To ensure that interventions for children who require AAC also address expressive language acquisition, this clinical focus article focuses on how to apply a developmental model of language acquisition to guide AAC decision making for preliterate aided communicators, with a particular focus on vocabulary selection.
METHOD: A brief review of early expressive language development is presented, along with arguments for why relying on a developmental model to guide AAC decision making is so critical. A series of detailed examples of how to apply a developmental model to various AAC vocabulary selection approaches are provided, including analyses of how well each approach aligns with pragmatic, semantic, grammatical, and narrative development.
CONCLUSIONS: No single AAC approach for preliterate AAC language learners adequately addresses both immediate and longer-term expressive language needs; every approach has both strengths and weaknesses. Clinical decision making requires an analysis of each approach to ensure that AAC service delivery teams clearly understand the inevitable linguistic gaps, with plans put into place to fill in those gaps with different approaches. Future efforts to improve preliterate AAC service provision should use a developmental model of language as a starting point, in combination with input from families, educators, and clinicians to ensure the feasibility of the chosen approaches.
This is a prospective, multi-center, clinical trial involving children aged 6 to 21 years with persistent cow's milk allergy. These children will be recruited from 2 sites (Johns Hopkins and Duke University) and will undergo initial screening and double-blind, placebo-controlled, food challenge (DBPCFC) to confirm threshold dose for reactivity to milk. Patients will be treated with milk oral immunotherapy (OIT) or placebo for 22-30 weeks. Those who reach an adequate maintenance dose for OIT will undergo a second DBPCFC. Those who develop desensitization will continue with daily milk intake and undergo a third DBPCFC. Those in the treatment group who are not desensitized will return to strict avoidance. Those in placebo group will be offered to begin treatment or continue with strict milk avoidance. Symptom and diet information will be collected initially and at regular intervals. Bloodwork, skin prick tests (SPTs), pulmonary function tests (PFTs), and oral secretion samples will be done initially and at periodic intervals.
Celiac disease is an immune-mediated enteropathy with typical symptoms of weight loss, abdominal bloating, diarrhea, vomiting, or constipation. Many shreds of evidence show that CeD is hereditary in origin and various biochemical pathways have been connected to its etiology. Numerous genes from different physiological pathways have been investigated in the last few decades, however a comprehensive analysis is required to address the gaps and provide a more integrated understanding of how these genetic factors contribute to the pathogenesis of disease. Present study attempts to summarize the historical and up-to-date findings to understand the role of genetics in Celiac disease. The literature was searched from sources such as PubMed and Google Scholar to analyze studies conducted on celiac disease from the years 1995 to 2024. Term maps were created to examine the frequency of studies related to various terms to understand the major focus of the studies till date. The study also concise the different genetic polymorphisms studied in a table to understand the role of genetics in celiac diseases. Early studies on celiac disease primarily focused on its pathophysiology, prevalence, and general aspects, with limited attention to genetics. However, recent studies have increasingly emphasized the genetic basis of the disease and highlighting the involvement of various pathways like inflammation, T-cell differentiation and activation, epithelial barrier function, stress and apoptosis pathways. However, present study indicate that most current research predominantly focus on cytokines, specifically the TNF alpha gene. Consequently, there is a need for additional research to gain a more comprehensive understanding of the genetics of celiac disease.
PROBLEM TO BE SOLVED: To obtain the subject medicinal preparation which contains evodiamene, one component in gosyuyuto, as an active ingredient, and can effectively treat autoimmune diseases such as type I diabetes or rheumatoid arthritis. SOLUTION: This medicinal preparation contains an evodiamine derivative represented by formula I (R is a 1-3C alkyl), preferably evodiamine of formula II as an active ingredient. This preparation inhibits the synthesis of proteins in the heat-shock protein group with a molecular weight of 57-68 kilodalton (abbreviated to protein in HSP family). The evodiamine is preferably extracted from gosyuyuto. This preparation can contain the evodiamine derivative in an amount of 0.01-99wt.%, preferably 0.1-80wt.%. Thus, this perparation can be expected to prevent and treat autommune diseases in which a protein belonging to the HSP family participates to its crisis in cells.
Hair treatment composition comprising; trimethylglycine, at least one linear diol with a chain length of 3-10 carbon atoms; at least one compound of formula (I); Wherein R1 and R2 are the same or different and represent a C­1-4­ alkyl radical; R3 and R4 are the same or different and are CH2-CH2-O(C=O)-R5, where R5 is a linear C10-30­ alkyl radical; X is halide; and at least one compound selected from the group of medium chain triglycerides having a chain length of 6-14 carbon atoms, preferably 8-10 carbon atoms; glycosides having a C10-30-alkyl radical, preferably C15-25; glycerol and mixtures thereof. The diol comprises a chain length of 4-6 carbon atoms and two primary hydroxy groups, in particular 1,2-dihydroxypentane. The compound of Formula (I) may be dimethyl-bis[2-[(1-oxooctadecyl)oxy]ethyl}]ammonium chloride. The hair treatment composition may be provided as a sprayable emulsion. The composition may be substantially free from silicone and/or mineral compounds. Cosmetic use of the air treatment compositions for improving the hair care properties of hair, particularly for improving the combability and untangling properties of wet and dry hair.
Methylcarbamate (MC), a reaction product between dimethyl dicarbonate and ammonia or ammonium ion, is a potent hepatocarcinogen in F344 rats. Various genotoxicity tests have shown negative results for MC. Although previous studies have described the effects of MC on the liver, including the formation of characteristic basophilic cytoplasmic inclusions (CIs) in hepatocytes, the toxicological significance of CIs and their involvement in hepatocarcinogenesis remain unclear. In the current study, to elucidate the mechanisms of MC hepatocarcinogenesis, we examined hepatotoxicity and genotoxicity after 4 weeks of administration of MC using gpt delta rats with an F344 genetic background as a reporter gene transgenic animal model. Histopathologically, single-cell necrosis, karyomegaly, and the formation of CIs positive for Feulgen staining were observed in hepatocytes at the carcinogenic dose, demonstrating the hepatotoxicity of MC. CIs were also detected as large micronuclei in liver micronucleus tests but not in the bone marrow, suggesting that MC could cause chromosomal instability specifically in the livers of rats. Reporter gene mutation assays demonstrated that MC did not induce mutagenicity even in the liver. Immunofluorescence analyses revealed that CIs exhibited loss of nuclear envelope integrity, increased heterochromatinization, and accumulation of DNA damage. An increase in liver STING protein levels suggested an effect on the cyclic GMP-AMP synthase/stimulator of interferon genes innate immune pathway. Overall, these data demonstrated the possible occurrence of chromothripsis-like chromosomal rearrangements via CIs. Thus, the formation of CIs could be a crucial event in the early stage of MC-induced hepatocarcinogenesis in F344 rats.
It is a single-blinded, single-center, randomized trial. Patients with septic shock established within 24 hours in the ICU of Tibet Autonomous Region People's Hospital will be screened for recruitment. After adequate fluid resuscitation, continuous infusion of norepinephrine is given to the patients to maintain a mean arterial pressure (MAP) of 65-75 millimeter of mercury (mmHg). Midazolam and fentanyl are given to achieve the goal sedation of bispectral index (BIS) 40-60, patients who are still with tachycardia (heart rate over 100 b.p.m.) will be recruited. After recruitment, patients in accordance with the random number table are divided into dexmedetomidine group, esmolol group and control group (T0). Patients in the two experimental groups are required to achieve the heart rate goal of 75-95 b.p.m. in one hour by adjusting the dose of dexmedetomidine or esmolol every twenty minutes. All patients acquired the hemodynamic evaluation at T1, T2, T3, T4 (6, 12, 18, 24hours after enrollment). The hemodynamic evaluation including transcranial Doppler of middle cerebral artery(MCA), deep middle cerebral vein (DMCV), basal vein Rosenthal (BVR) and transverse sinus (TS), hemodynamic parameters acquired by the pressure-recording analytical method through peripheral arterial with Mostcare. Demographic characteristics, diagnosis, laboratory reports and drug dose are collected during the study.
The present invention discloses an alcohol-relieving brain-sobering up health-care noodle in soup, which is prepared from physic liquor obtained by decocting pueraria roots, sterculia, lophatherum, coix seeds, tangerine peel, poria and liquorice, 175 g of high-quality fine dried noodles (or manually noodles), tomatoes (tomato paste), apium, packchoi, spinach, jujube soup, a proper amount of salt, monosodium glutamate, fistular onion flowers fried by sesame oil, shredded ginger, etc. The physic liquor is prepared by the following steps: pouring the prepared raw materials into a vessel according to formula proportion, adding water for immersion, clearing away dust, sand and impurities on the surface, decocting, packaging the filtered physic liquor for the alcohol-relieving noodle in soup in small bags in a fixed quantity and in a vacuum mode, packing in boxes and warehousing. The seasoning is prepared by the following steps: pouring the prepared tomato (tomato paste), the apium, the packchoi, the spinach, etc. into a vessel according to proportion requirements, adding water and additives for immersion, clearing away dust, sand and impurities on the surface and cutting after washing for standby; preparing the jujube soup, the salt, the monosodium glutamate, the fistular onion flowers fried by sesame oil and the shredded ginger in a proper amount. The present invention has the advantages of simple preparation process and working procedure, sufficient source of raw materials, capability of various production scales, no condition limitation, low cost, obvious effect on relieving alcohol and no toxic or side effect. The energy of an alcohol user can recover quickly. The present invention can quickly relieve the symptoms of discomfort of the liver and the stomach of the alcohol user and nausea, and has the effects of health care and dietotherapy.
FIELD: medicine. SUBSTANCE: method involves determining biological effectiveness of glucocorticoids applying formula reflecting interdependence of polymorphonuclear leukocytes and contractile capacity of myocardium with glucocorticoid activity. Prednisolone and hyperbaric oxygenation therapy is carried out. The glucocorticoid dose and excessive pressure magnitude are determined as inverse dependent ones with respect to biological effectiveness of glucocorticoids. The latter being increased, hormone dose is reduced to the point of its canceling. EFFECT: enhanced effectiveness of treatment.
FIELD: medicine, skin transplantation. SUBSTANCE: composition equivalent of living skin comprises epidermal layer of cultured keratinocytes, layer of porousless collagen and dermal layer of cultured fibroblasts in spongy matrix cross-linked by porous collagen. Preferable porousless collagen is bovine collagen of type 1, type 3 or their mixture treated with pepsin. Invention describes a method of skin equivalent preparing and test-set for the skin equivalent testing in vitro. Indicated skin equivalent can be used for skin transplantation and for assay of effects of different substances on skin in vitro. EFFECT: broadened functional capabilities. 8 cl, 5 dwg, 2 ex
PURPOSE:To obtain the subject composition prevented from discoloration and deterioration with time, useful for preventing and treating periodontosis, by formulating a water-soluble zinc salt in a lysozyme-contg. composition for oral cavity. CONSTITUTION:This composition can be obtained by formulating a composition for oral cavity containing lysozyme or a salt thereof with 0.05-1wt.% of a water- soluble zinc salt (e.g. zinc sulfate), 0.5-3wt.% of a water-soluble nonionic surfactant (e.g. sucrose ester), and 0.1-1wt.% of an alkylimidazolinium betaine or a salt thereof. The lysozyme, which has germicidal and anti-inflammatory activity owing to its bacteriolytic activity, is useful for preventing and treating oral cavity diseases. By the combined use of the lysozyme with the alkylimidazolinium betaine and/or nonionic surfactant, this composition presents its germicidal and anti-inflammatory activity sufficiently and stably even after preserved for a long period of time without inhibiting lysozyme activity. This composition is highly foamable, being excellent in feeling during or after use without bitter or offensive taste.
There is a growing evidence suggesting the association of vitamin D deficiency (VDD) and cognitive impairment. In this study we evaluated the possible involvement of gut microbiota in the cognitive impairments mediated by VDD and investigated the effects of pharmacological treatment with the oxazoline derivative of the aliamide palmitoylethanolamide, 2-Pentadecyl-2-oxazoline (PEA-OXA). Mice were submitted to behavioural, biochemical and electrophysiological analysis to assess whether their vitamin D status affected cognitive performance together with gut microbiota composition. In VDD mice we found cognitive malfunctioning associated with reduced neuroplasticity, indicated by impaired long term potentiation, and neuroinflammation at the hippocampal level. Importantly, PEA-OXA counteracted the cognitive impairments and modified the biochemical and functional changes induced by VDD. Additionally, PEA-OXA treatment enhanced gut microbiota diversity, which tended to be decreased by VDD only in female mice, elevated the relative abundance of lactic and butyric acid-producing families, i.e. Aerococcaceae and Butyricicoccaceae, and reversed the VDD-induced decrease of butyrate-producing beneficial genera, such as Blautia in female mice, and Roseburia in male mice. These data provide novel insights for a better understanding of the cognitive decline induced by VDD and related gut dysbiosis and its potential therapeutic treatment.
DR is the most common diabetic eye disease and is the leading cause of blindness in adults in the United States. It is caused by damage to the blood vessels of the retina, which is the light-sensitive outer layer of the eye. Retinal blood vessels are often affected by the high blood sugar levels associated with diabetes. Older people have an increased risk of developing DR; however, DR is likely to occur earlier and be more severe in anyone who has poorly controlled diabetes. Almost everyone who has had diabetes for more than 30 years will eventually show signs of DR. Symptoms of DR include poor night vision, seeing spots in front of the eyes, blurred vision, and blindness. The ACCORD study is a study that is examining the effects of different treatments on cardiovascular disease in people with diabetes. Participants in the ACCORD study will receive one of eight different combinations of treatment, including blood sugar control, blood pressure control, and cholesterol-controlling medication. This study will enroll participants in the ACCORD study and will examine the effects of the study treatments on DR. The results from this study may be used to develop new treatments to help prevent diabetes-related blindness.

Study visits will occur at baseline and Year 4. At each study visit, participants will have an eye exam and specialized fundus photographs taken of the back of the eye and retina.
Patients will receive dexamethasone IV on Days 1 to 3. Additionally, in accordance with local treatment guidelines, patients in this group may receive a regulatory-approved antiviral treatment.
Tobacco carcinogens metabolism-related genes (TCMGs) could generate reactive metabolites of tobacco carcinogens, which subsequently contributed to multiple diseases. However, the association between genetic variants in TCMGs and bladder cancer susceptibility remains unclear. In this study, we derived TCMGs from metabolic pathways of polycyclic aromatic hydrocarbons and tobacco-specific nitrosamines, and then explored genetic associations between TCMGs and bladder cancer risk in two populations: a Chinese population of 580 cases and 1101 controls, and a European population of 5930 cases and 5468 controls, along with interaction and joint analyses. Expression patterns of TCMGs were sourced from Nanjing Bladder Cancer (NJBC) study and publicly available datasets. Among 43 TCMGs, we observed that rs7087341 T > A in AKR1C2 was associated with a reduced risk of bladder cancer in the Chinese population [odds ratio (OR) = 0.84, 95% confidence interval (CI) = 0.72-0.97, P = 1.86 × 10-2]. Notably, AKR1C2 rs7087341 showed an interaction effect with cigarette smoking on bladder cancer risk (Pinteraction = 5.04 × 10-3), with smokers carrying the T allele increasing the risk up to an OR of 3.96 (Ptrend < 0.001). Genetically, rs7087341 showed an allele-specific transcriptional regulation as located at DNA-sensitive regions of AKR1C2 highlighted by histone markers. Mechanistically, rs7087341 A allele decreased AKR1C2 expression, which was highly expressed in bladder tumors that enhanced metabolism of tobacco carcinogens, and thereby increased DNA adducts and reactive oxygen species formation during bladder tumorigenesis. These findings provided new insights into the genetic mechanisms underlying bladder cancer.
The intervention in the experimental group (EG) consists of a exercise therapy and adapted physical activity program based on racket sports. The immediate EG will receive sixteen, twice a week, one-hour sessions of group-based, racket sports specific fundamental movement skills training. All sessions will be guided and supervised by a physiotherapist and delivered in groups of 5 participants to promote exchange and conviviality and to optimize the rates of participation and compliance.
Vimizim does not contain preservatives; therefore the product should be used immediately after dilution. If immediate use is not possible, the diluted product may be stored for up to 24 hours at 2°C to 8°C (36°F to 46°F) followed by up to 24 hours at 23°C to 27°C (73°F to 81°F). Administration of Vimizim should be completed within 48 hours from the time of dilution. Vials are for single-use only. Discard any unused product. Do not freeze or shake. Protect from light.
Medication non-adherence represents an important threat to the health of the Western people. A large number of pharmacy records based studies demonstrated that adherence to lipid lowering treatment in daily practice is substantially worse compared to adherence observed in the controlled setting of randomized controlled trials. In addition, the relationship between non-adherence with statin-treatment assessed with pharmacy records and cardiovascular outcomes has been convincingly demonstrated. This implies that pharmacy records can and should be used to identify non-adherent patients and thus patients at risk for major cardiovascular events. Using this data, community pharmacists can play a more substantive role in developing the concept of pharmaceutical care. The objective of the study is to test the effectiveness of a community pharmacist-led intervention to increase adherence to lipid lowering treatment.
This is a single arm study of subjects who have an external wound that is currently measured for length and width using a ruler. A study subject may have up to 3 qualifying external wounds.
The Telephone-Administered Motivational Interviewing Plus Behavioral Skills Training (teleMI+BST) intervention comprises 5 sessions lasting approximately 45-50 minutes each. Sessions occur in weeks 3, 4, 8, and 12 post-enrollment, with a follow-up booster session in week 24. The Information-Motivation-Behavioral Skills (IMB) Model (Fisher \& Fisher, 1992) provides the theoretical framework for behavior change mechanisms of teleMI+BST. The IMB posits that knowledge about condom use practices, condom use motivation, and acquisition and application of requisite condom use skills lead to engagement in condom-protected sex. The focus of this intervention is to help participants process ambivalence about engaging in condomless sex acts that risk HIV transmission.
Dimer diol derivatives of chemical formula 19 in which R is a dimer diol residue, each of X and Y are independently hydrogen, chemical formula 20 or chemical formula 21, except X and Y are not both hydrogen. In each of chemical formulae 20 and 21, R1 is an aliphatic hydrocarbon group having 1 to 22 carbon atoms, Z is chemical formula 22 and/or chemical formula 23 and n is an integer including zero. In each of chemical formulae 22 and 23, R1 is an aliphatic hydrocarbon group having 1 to 22 carbon atoms. Dimer diol residue R is preferably a cyclohexyl moiety substituted by two alkyl groups and two alkylenyl groups to which the oxygen atoms of chemical formula 19 are attached. The dimer diol derivatives have excellent water-holding properties, excellent pigment dispersion properties and a high level of safety. The derivatives may be used in cosmetics such as emollient creams and liquid foundations.